指南与共识中毒与环境急症

CDC发布阿片类药物指南后加州中毒控制系统报告的阿片与苯二氮䓬联合及单一暴露趋势

Trends in concomitant and single opioid and benzodiazepine exposures reported to the California Poison Control System following the Centers for Disease Control and Prevention release of opioid guidelines in 2016.
指南 / 共识 · Clin Toxicol (Phila) · 2023-03-29
一句话结论CDC指南发布后,加州中毒控制系统单一阿片和单一苯二氮䓬暴露每月显著减少,但联合暴露无显著变化,且联合暴露和单一阿片暴露相关严重结局每月显著增加。

这项回顾性观察研究分析了2012年1月至2021年6月加州中毒控制系统报告的阿片和苯二氮䓬暴露(单独或联合),用中断时间序列分析比较CDC指南发布前后每月呼叫量差异。结果显示联合暴露无显著变化;单一阿片和单一苯二氮䓬暴露分别显著减少1.07(95% CI:-1.62,-0.51)和1.82(95% CI:-2.33,-1.31)次/月;但与严重医疗结局相关的联合暴露和单一阿片暴露分别显著增加0.11(95% CI:0.04,0.18)和0.2(95% CI:0.05,0.34)次/月。作者认为指南未与联合中毒暴露相应减少相关,可能需要额外干预。

要点

  • 指南发布后,单一阿片暴露每月显著减少1.07次(95% CI:-1.62,-0.51),单一苯二氮䓬暴露每月显著减少1.82次(95% CI:-2.33,-1.31)。
  • 指南发布前后,阿片与苯二氮䓬联合暴露每月呼叫量无显著变化。
  • 与严重医疗结局相关的联合暴露每月显著增加0.11次(95% CI:0.04,0.18),单一阿片暴露每月显著增加0.2次(95% CI:0.05,0.34)。
  • 作者认为指南未与联合中毒暴露减少相关,可能需要额外干预以减少阿片与苯二氮䓬联合暴露。

适用人群与场景

  • 2012年1月至2021年6月向加州中毒控制系统报告的阿片和苯二氮䓬暴露(单独或联合)病例。

研究设计与关键结果

  • 研究类型为回顾性观察研究,分析2012年1月至2021年6月加州中毒控制系统报告的阿片和苯二氮䓬暴露(单独或联合)。
  • 采用中断时间序列分析比较指南发布前后每月呼叫量差异。
  • 指南发布前后,阿片与苯二氮䓬联合暴露每月呼叫量无显著变化。
  • 与指南发布前相比,单一阿片暴露每月显著减少1.07次(95% CI:-1.62,-0.51),单一苯二氮䓬暴露每月显著减少1.82次(95% CI:-2.33,-1.31)。
  • 对于与严重医疗结局相关的暴露,指南发布后联合暴露每月显著增加0.11次(95% CI:0.04,0.18),单一阿片暴露每月显著增加0.2次(95% CI:0.05,0.34)。

证据类型、等级与局限

  • 证据类型:回顾性观察研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为指南未与联合中毒暴露相应减少相关,可能需要额外干预以减少阿片与苯二氮䓬联合暴露。

指南或共识出处

  • Centers for Disease Control and Prevention(CDC)于2016年3月发布的《Guideline for Prescribing Opioids for Chronic Pain》。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: In March 2016, the Centers for Disease Control and Prevention released the Guideline for Prescribing Opioids for Chronic Pain, intended for primary care clinicians. One recommendation advised against concurrent prescription of opioids and benzodiazepines. Although existing research suggests a reduction in co-prescribing of these drug classes by clinicians after guideline release, there are limited data assessing its possible effect on patient medical outcomes, such as overdoses.

METHODS: This retrospective observational study analyzed opioid and benzodiazepine exposures, alone or in combination, reported to the California Poison Control System from January 2012 to June 2021. Interrupted time series analyses identified the difference in monthly call volume between pre- and post-guideline release. For exposures resulting in serious medical outcomes, additional analyses assessed trends and identified associated variables.

RESULTS: There was no significant change in concomitant opioid and benzodiazepine exposures reported to California Poison Control System between pre- and post-guideline release. Compared to pre-guideline release, exposures to a single opioid or to a single benzodiazepine significantly decreased by 1.07 (95% CI: -1.62, -0.51) and 1.82 (95% CI: -2.33, -1.31) calls per month, respectively, after the guideline release. For exposure calls associated with serious medical outcomes, there was a significant increase of 0.11 (95% CI: 0.04, 0.18) and 0.2 (95% CI: 0.05, 0.34) calls per month for concomitant opioid and benzodiazepine and single opioid exposures, respectively, following guideline release.

DISCUSSION: The guideline release appeared to have a variable association with exposures to single opioid, single benzodiazepines, and concomitant opioid and benzodiazepine cases reported to California Poison Control System. Although exposures to opioids or benzodiazepines alone significantly decreased after guideline release, there was no significant change in concomitant exposures. Additionally, for exposures associated with serious medical outcomes, concomitant exposures, and single opioid exposures significantly increased following guideline release.

CONCLUSION: Our results suggest that the guideline was not associated with a corresponding decrease in the number of concomitant poisoning exposures reported to California Poison Control System. Additional interventions may be needed to reduce concomitant exposures to opioids and benzodiazepines.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Chu E, Cocos G, Lee HJ, et al. Trends in concomitant and single opioid and benzodiazepine exposures reported to the California Poison Control System following the Centers for Disease Control and Prevention release of opioid guidelines in 2016. Clin Toxicol (Phila). 2023. PMID: 36988441. doi:10.1080/15563650.2022.2158095

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。